CTLA4 and sarcoma: Mice colonized with responder NSCLC stool and subsequently colonized with a sarcoma line also responded to anti–CTLA-4 therapy (6), and we have observed that mice colonized with responder melanoma stool and subsequently implanted with a colon carcinoma also respond to anti–PD-L1 therapy (8).